Efficacy and safety of angiogenesis inhibitor combined with erlotinibin the targeted treatment of EGFR-mutated advanced non-small celllung carcinoma: a Meta-analysis

doi:10.3781/j.issn.1000-7431.2023.2205-0334

PDF(2722 KB)

Tumor ›› 2023, Vol. 43 ›› Issue (01) : 29-41. DOI: 10.3781/j.issn.1000-7431.2023.2205-0334

Efficacy and safety of angiogenesis inhibitor combined with erlotinibin the targeted treatment of EGFR-mutated advanced non-small celllung carcinoma: a Meta-analysis

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 43(01): 29-41 https://doi.org/10.3781/j.issn.1000-7431.2023.2205-0334

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(2722 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Accepted	Published
2022-05-15	2022-12-06	2023-01-25
Issue Date
2023-01-25

Please choose a citation manager

Content to export

HeighLight

Abstract

Key words

QR code of this article

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

References

{{custom_fnGroup.title_en}}

Footnotes

{{custom_ack.title_en}}

Funding

RIGHTS & PERMISSIONS